Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Genomic Associations in DLBCL

Searching for loci associated with survival

Publish date:: October 14, 2015

Associations between loci at 5q23.2 and 6q21 with event-free survival (EFS) and overall survival (OS) in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy, suggest a novel biology and the potential contribution of host genetics to the prognosis of this aggressive malignancy. This according to meta-analysis of 4 separate studies comprising 1,537 patients with DLBCL treated with immunochemotherapy. Researchers found:

• The top loci for EFS were marked by rs7712513 at 5q23.2 and rs7765004 at 6q21, although they did not reach conventional genome-wide significance.

• Both rs7712513 and rs7765004 were also associated with OS.

• In exploratory analysis, a two-single nucleotide polymorphism risk score was highly predictive of EFS and was independent of treatment, International Prognostic Index, and cell-of-origin classification.

Citation: Ghesquieres H, Slager SL, Jardin F, et al. Genome-wide association study of event-free survival in diffuse large B-cell lymphoma treated with immunochemotherapy. [Published online ahead of print October 12, 2015]. Clin Oncol. doi: 10.1200/JCO.2014.60.2573.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Aggressive Lymphomas

Study Halted; ‘Hyperprogression’ Seen With Nivolumab for R/R PTCL,

CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma,

Bispecific CAR T-cell Therapy Yields Complete Responses in Relapsed/Refractory non-Hodgkin Lymphomas,

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL,